BN Business News
Add your company to Business Communicator →

BUSINESS NEWS

Search Business News

Find articles by title or summary.

8/8/2024

FAA Proposes Airworthiness Directive for MD Helicopters Helicopters

The FAA proposes a new airworthiness directive for certain MD Helicopters models due to a seized and damaged roller bearing in the pilot interconnecting cyclic torque tube assembly, requiring repetitive inspections and potential replacement or additional inspections.

8/8/2024

FAA Proposes Amendment to VOR Federal Airways in Eastern United States

The Federal Aviation Administration (FAA) is proposing to amend four domestic Very High Frequency Omnidirectional Range (VOR) Federal Airways in the eastern United States, primarily due to the planned decommissioning of the Roanoke, VA VOR/Distance Measuring Equipment (VOR/DME).

8/8/2024

FAA Corrects RNAV Routes in Eastern United States

The Federal Aviation Administration (FAA) has corrected a final rule establishing three new RNAV Routes and amending three existing routes in the eastern United States to support the Next Generation Air Transportation System (NextGen).

8/8/2024

Indoxacarb Pesticide Tolerances Established

The U.S. government has set tolerances for indoxacarb residues in multiple crops, following a request from Interregional Research Project Number 4 under the Federal Food, Drug, and Cosmetic Act.

8/8/2024

EPA Proposes Consent Decree to Address Lawsuit Over Air Quality Review

The Environmental Protection Agency (EPA) has proposed a consent decree to address a lawsuit filed by the Center for Biological Diversity, Sierra Club, and Center for Environmental Health, alleging the EPA failed to complete a review of air quality criteria and standards. The decree would establish deadlines for the EPA to take actions in its review.

8/8/2024

Final Modifications to the Safer Choice Standard and a Provision for a Safer Choice Cleaning Service Certification Program; Notice of Availability

The Environmental Protection Agency (EPA) is announcing the availability of the final, updated Safer Choice and Design for the Environment (DfE) Standard, which includes changes to the Standard's title, packaging criteria, and certification for cleaning service providers. The update aims to help consumers and businesses find safer products for human health and the environment.

8/8/2024

FCC Approves Numbering Policies for Modern Communications for Three Years

The Wireline Competition Bureau announces that the Office of Management and Budget has approved the information collection associated with the Commission's revised Numbering Authorization Application rules for a period of three years. This approval is consistent with the FCC's Numbering Policies for Modern Communications, Second Report and Order (FCC 23-75).

8/8/2024

USDA Renews 47 Organic Substances, Completes 2025 Sunset Review

The US Department of Agriculture has renewed 47 substances listed on the National List of Allowed and Prohibited Substances, following the outcome of the 2025 sunset review processes and recommendations from the National Organic Standards Board.

8/8/2024

FDA Renews Blood Products Advisory Committee Charter for 2 Years

The Food and Drug Administration (FDA) has renewed the Blood Products Advisory Committee charter for an additional 2 years, with the new term set to expire on May 13, 2026, following a determination by the Commissioner of Food and Drugs that it is in the public interest to do so.

8/8/2024

FDA Reopens Comment Period for Over-the-Counter Monograph M013

The US Food and Drug Administration is reopening the public comment period for a proposed rule to amend the regulation of over-the-counter pain relievers and anti-inflammatory medications, due to technical issues with the FDA's online portal, and is now accepting comments through the Federal eRulemaking portal.

8/8/2024

FDA Clears DELATESTRYL for Continued Sale

The US Food and Drug Administration (FDA) has ruled that DELATESTRYL (Testosterone Enanthate) Injection, 200 milligrams per milliliter, and other related drug products were not withdrawn from sale due to safety or effectiveness concerns, allowing them to continue being approved for use in abbreviated new drug applications (ANDAs).